ABBV
AbbVie Inc.
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. Its portfolio includes immunology medicines such as Humira, Skyrizi, and Rinvoq; oncology products including Imbruvica and Venclexta; neuroscience treatments such as Botox Therapeutic, Vraylar, and Ubrelvy; aesthetics products including Botox Cosmetic and Juvederm; and eye-care, women's health, and other specialty therapies. The company markets products directly and through wholesalers, distributors, and specialty pharmacies to healthcare providers, hospitals, and government customers.
Coverage
Medicaid's MFN Rebate Stacks on a 62-77% Discount. Mississippi Already Beats It.
The White House will say all 50 states get most-favored-nation Medicaid pricing. It stacks on existing rebates, and a July study says Mississippi wins now.
AbbVie Q2 2026: Skyrizi and Rinvoq Keep Compounding — Stock Falls on a Narrow EPS Miss
AbbVie beat revenue estimates as Skyrizi and Rinvoq grew over 24% each, but adjusted EPS missed by 6 cents and full-year guidance came down, sending shares down nearly 5%. We break down the immunology growth story against the near-term guidance drag.
Where the revenue goes next
Latest: $16.99B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $12.90B |
| 2020Q4 | $13.86B |
| 2021Q1 | $13.01B |
| 2021Q2 | $13.96B |
| 2021Q3 | $14.34B |
| 2021Q4 | $14.89B |
| 2022Q1 | $13.54B |
| 2022Q2 | $14.58B |
| 2022Q3 | $14.81B |
| 2022Q4 | $15.12B |
| 2023Q1 | $12.22B |
| 2023Q2 | $13.87B |
| 2023Q3 | $13.93B |
| 2023Q4 | $14.30B |
| 2024Q1 | $12.31B |
| 2024Q2 | $14.46B |
| 2024Q3 | $14.46B |
| 2024Q4 | $15.10B |
| 2025Q1 | $13.34B |
| 2025Q2 | $15.42B |
| 2025Q3 | $15.78B |
| 2025Q4 | $16.62B |
| 2026Q1 | $15.00B |
| 2026Q2 | $16.99B |
Latest: $2.03 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $1.29 |
| 2020Q4 | −$0.13 |
| 2021Q1 | $1.99 |
| 2021Q2 | $0.42 |
| 2021Q3 | $1.78 |
| 2021Q4 | $2.26 |
| 2022Q1 | $2.51 |
| 2022Q2 | $0.51 |
| 2022Q3 | $2.21 |
| 2022Q4 | $1.40 |
| 2023Q1 | $0.13 |
| 2023Q2 | $1.14 |
| 2023Q3 | $1.00 |
| 2023Q4 | $0.45 |
| 2024Q1 | $0.77 |
| 2024Q2 | $0.77 |
| 2024Q3 | $0.88 |
| 2024Q4 | −$0.03 |
| 2025Q1 | $0.72 |
| 2025Q2 | $0.52 |
| 2025Q3 | $0.10 |
| 2025Q4 | $1.02 |
| 2026Q1 | $0.39 |
| 2026Q2 | $2.03 |
Latest: 71.1 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | 14.9 |
| 2020Q4 | 30.6 |
| 2021Q1 | 31.6 |
| 2021Q2 | 25.4 |
| 2021Q3 | 21.7 |
| 2021Q4 | 18.0 |
| 2022Q1 | 20.1 |
| 2022Q2 | 18.9 |
| 2022Q3 | 15.8 |
| 2022Q4 | 21.7 |
| 2023Q1 | 33.8 |
| 2023Q2 | 25.1 |
| 2023Q3 | 37.4 |
| 2023Q4 | 52.5 |
| 2024Q1 | 50.4 |
| 2024Q2 | 53.9 |
| 2024Q3 | 65.2 |
| 2024Q4 | 71.0 |
| 2025Q1 | 86.3 |
| 2025Q2 | 86.3 |
| 2025Q3 | 172.8 |
| 2025Q4 | 96.8 |
| 2026Q1 | 107.1 |
| 2026Q2 | 71.1 |
Latest: $3.11B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $5.61B |
| 2020Q4 | $4.58B |
| 2021Q1 | $4.69B |
| 2021Q2 | $4.70B |
| 2021Q3 | $7.72B |
| 2021Q4 | $4.89B |
| 2022Q1 | $4.75B |
| 2022Q2 | $4.86B |
| 2022Q3 | $7.42B |
| 2022Q4 | $7.21B |
| 2023Q1 | $4.02B |
| 2023Q2 | $6.14B |
| 2023Q3 | $7.36B |
| 2023Q4 | $4.55B |
| 2024Q1 | $3.85B |
| 2024Q2 | $2.03B |
| 2024Q3 | $5.20B |
| 2024Q4 | $6.76B |
| 2025Q1 | $1.40B |
| 2025Q2 | $4.88B |
| 2025Q3 | $6.64B |
| 2025Q4 | $4.89B |
| 2026Q1 | $3.56B |
| 2026Q2 | $3.11B |
Latest: 1.77B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | 1.77B |
| 2020Q4 | 1.77B |
| 2021Q1 | 1.77B |
| 2021Q2 | 1.78B |
| 2021Q3 | 1.78B |
| 2021Q4 | 1.77B |
| 2022Q1 | 1.78B |
| 2022Q2 | 1.78B |
| 2022Q3 | 1.78B |
| 2022Q4 | 1.77B |
| 2023Q1 | 1.78B |
| 2023Q2 | 1.77B |
| 2023Q3 | 1.77B |
| 2023Q4 | 1.77B |
| 2024Q1 | 1.77B |
| 2024Q2 | 1.77B |
| 2024Q3 | 1.77B |
| 2024Q4 | 1.77B |
| 2025Q1 | 1.77B |
| 2025Q2 | 1.77B |
| 2025Q3 | 1.77B |
| 2025Q4 | 1.77B |
| 2026Q1 | 1.77B |
| 2026Q2 | 1.77B |
Latest: $184.69B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $69.48B |
| 2020Q4 | $74.06B |
| 2021Q1 | $78.75B |
| 2021Q2 | $83.44B |
| 2021Q3 | $91.16B |
| 2021Q4 | $96.05B |
| 2022Q1 | $100.80B |
| 2022Q2 | $105.66B |
| 2022Q3 | $113.08B |
| 2022Q4 | $120.30B |
| 2023Q1 | $124.32B |
| 2023Q2 | $130.46B |
| 2023Q3 | $137.81B |
| 2023Q4 | $142.36B |
| 2024Q1 | $146.21B |
| 2024Q2 | $148.24B |
| 2024Q3 | $153.44B |
| 2024Q4 | $160.19B |
| 2025Q1 | $161.59B |
| 2025Q2 | $166.48B |
| 2025Q3 | $173.12B |
| 2025Q4 | $178.01B |
| 2026Q1 | $181.57B |
| 2026Q2 | $184.69B |
Latest earnings
Company History
AbbVie was formed as a spin-off from Abbott Laboratories, focusing on research-based pharmaceuticals; became independent on January 1, 2013.
Acquired ImmuVen, a startup focused on biotherapeutics for cancer, infectious diseases, and autoimmune disorders.
Acquired oncology firm Pharmacyclics and its blood cancer treatment ibrutinib for $21 billion.
Acquired Allergan for $63 billion, with divestitures to gain regulatory approval, including brazikumab to AstraZeneca and Zenpep/Viokace to Nestlé.
Evaluated Kaletra (lopinavir/ritonavir) as a potential COVID-19 treatment, later found ineffective, and ceased patent enforcement in response to government pressure.
Acquired ImmunoGen for $10.1 billion to enter the ovarian cancer market with the drug Elahere.
Robert Michael replaced Richard Gonzalez as CEO, with Gonzalez becoming executive chairman.
Key Players
showing 6 of 18
The CEO view — 0 podcasts, interviews & articles →
Similar stocks in Healthcare
Funds we follow holding ABBV
By latest reported 13F position value. Market value at quarter-end, not cost basis.
